Jazz Pharmaceuticals plc announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 8-11, 2025, in Seattle. Research to be presented at the meeting include dual late-breaking poster and oral presentations, which highlight the extensive Phase 4 data evaluating the effectiveness of low-sodium oxybate, Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These presentations include the first interim results from the open-label, single arm XYLO trial that evaluated ambulatory and office blood pressure changes in patients with narcolepsy after switching from a twice-nightly high-sodium oxybate oral solution to low-sodium oxybate, Xywav.
Two additional presentations share novel results from the open-label, single arm DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, which assessed Xywav on multiple sleep parameters, including the first presentation of polysomnography (PSG) outcomes in adults with IH. Additional data evaluated the effectiveness and safety of Xywav in a cohort of narcolepsy patients whose doses were optimized to greater than 9 grams (with twice-nightly dosing). The Xywav label recommends a maximum nightly dose of 9 grams per night.
Additional highlights at SLEEP 2025 include: · Two late-breaking poster presentations describing results from the CHIME study, which evaluated real-world, patient-reported outcomes, including treatment adherence, effectiveness, and satisfaction among adults with narcolepsy or IH (reported separately) taking Xywav. A late-breaking claims analysis that describes self-reported prevalence, severity, and impact of sleep inertia among individuals diagnosed with IH. Two additional late-breaking poster presentations showcasing findings from INTREPID, a retrospective cohort study that examined Optum Market Clarity data from 2007?2023 to assess treatment patterns and changes in alerting agent claims among patients with narcolepsy or IH during the full study period and following the approval of Xywav.
Two poster presentations showcasing sleep architecture results from the DUET trial, which demonstrated the effectiveness of Xywav on improvements in sleep quality among patients with IH or narcolepsy. Two poster presentations report interim results from the LYRICAL study, which examined real-world and patient-reported data showing patients in both the narcolepsy and IH cohorts taking Xywav experience symptom improvements, improved quality of life and high global treatment satisfaction.
